Session 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives
|
|
- Elfrieda Young
- 8 years ago
- Views:
Transcription
1 Session 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives 1. Design strategies to help patients overcome cultural barriers to using insulin, and apply a team-based approach to initiating, switching, and intensifying insulin therapies. 2. Employ the tenets of physiologic insulin replacement, and select between various insulin formulations to help patients meet individualized treatment target goals.
2 Session 5 Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Faculty Javier Morales, MD Vice President Principal Clinical Trials Investigator Advanced Internal Medicine Group, P.C. New Hyde Park, New York Dr Morales is in private practice with the Advanced Internal Medicine Group in New Hyde Park, New York. After graduating from the University of Medicine and Dentistry of New Jersey, he completed residencies at Memorial Sloan-Kettering Cancer Center and North Shore University Hospital, where he served as chief medical resident. Dr Morales serves on multiple committees at St. Francis Hospital in Roslyn, New York. In addition to authoring several publications, he has served as principal investigator for several different studies and clinical trials. He is active in the educational sector and has been a presenter at many Pri-Med symposia. He also serves as a clinical instructor for several nurse practitioner, physician assistant, and internal medicine residency programs at North Shore University Hospital and Winthrop University Hospital. Dr Morales is an avid musician and percussionist, and he is fluent in Spanish, Italian, and Portuguese. Faculty Financial Disclosure Statement The presenting faculty reports the following: Dr Morales is consultant for Novo Nordisk Inc., Warner Chilcott, Eli Lilly and Company, Liposcience, and Boehringer Ingelheim. Suggested Reading List Handelsman Y, Mechanick JI, Blonde L, et al. AACE Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 211;17(suppl 2):1-53. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. April 19, 212. doi:1.2337/dc Peyrot M, Rubin RR, Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Primary Care Diabetes. 21;4(suppl 1):S11-S18. Unger J. Insulin initiation and intensification in patients with T2DM for the primary care physician. Diabetes Metab Syndr Obes. 211;4: Epub 211 Jun 28.
3 Faculty Disclosure Session 5 2: PM 3:3 PM Dr Morales is a consultant for Novo Nordisk Inc., Warner Chilcott, Eli Lilly and Company, Liposcience, and Boehringer Ingelheim. Insulin: Tried and True Update on Best Practices in Clinical Use and Patient Adherence Javier Morales, MD 2 Learning Objectives Question Pre-test #1 Design strategies to help patients overcome cultural barriers to using insulin, and apply a team-based approach to initiating, switching and intensifying insulin therapies Employ the tenets of physiologic insulin replacement, and select between various insulin formulations to help patients meet individualized treatment target goals. In patients on oral T2DM agents, at what A1C level should insulin therapy be initiated? 1. >7.5% 2. >8.% 3. >8.5% 4. >9.% 5. Any of the above 3 4 Question Pre-test #2 You seek to initiate insulin therapy in a poorly-controlled patient but she thinks this will be too complex for her to do. How will you address this? Check all that apply (press <<send>> after each selection) 1. Tell her that insulin is her only option at this point in time 2. Institute self-adjustment algorithms with glucose monitoring 3. Start with basal insulin twice daily 4. Address insulin myths that it causes complications, damages the pancreas 5. Institute a pre-mixed fixed-dose insulin regimen Pre-Test Question #3: A pre-/post- blood glucose delta value that s less than 5 mg/ml might indicate: 1. Concurrent illness, eg, flu 2. Missed previous insulin dose 3. Previous insulin dose is too high 4. Insulin solution has expired or is denatured 5 6 1
4 The History of Diabetes Survival Stepwise Treatment of T2DM: Role of Insulins Years year old 3 year old 5 year old Insulin Initiation Intensification Further Intensification Basal Plus Add insulin at main meal Basal Add basal insulin and titrate Additional OADs ± Incretins Basal-Bolus Information taken from: Bliss M. The Discovery of Insulin. University of Chicago Press Photographs courtesy of the National Library of Medicine Lifestyle Changes + Metformin Progressive deterioration of beta-cell function 8 A1C % A1C % A1C > 9.% Drug Naive Under Treatment 212 ADA/EASD Consensus Statement Recommendations Symptoms No Symptoms MET + GLP-1 or DPP4 Monotherapy MET DPP4 GLP-1 TZD AGI 2-3 Mos. Dual Therapy GLP-1 or DPP4 TZD MET + Glinide or SU TZD + GLP-1 or DPP4 MET + Triple Therapy + Colesevelam AGI 2-3 Mos. TZD Glinide or SU 2-3 Mos. INSULIN ± Other Agent(s) MET + MET + Dual Therapy GLP-1 or DPP4 or TZD SU or Glinide 2-3 Mos. Triple Therapy GLP-1 or DPP4 GLP-1 or DPP4 TZD 2-3 Mos. INSULIN ± Other Agent(s) + TZD + SU INSULIN ± Other Agent(s) ME T Dual or Triple Therapy + AGI DPP4 GLP-1 Met SU TZD GLP-1 or DPP4 TZD GLP-1 or DPP4 ±SU ±TZD α-glucosidase Inhibitor DPP-4 Inhibitor Incretin Mimetic Metformin Sulfonylurea Thiazolidinedione INSULIN ± Other Agent(s) Adapted and modified from: Rodbard H, Jellinger P, et al. Endocrine Practice, 29 Sept/Oct; 15 (6): Continue Current Management Sulfonylurea *pioglitazone TZD* Yes Diagnosis of Type 2 Diabetes Lifestyle Intervention + Metformin DPP 4 Inhibitor Inzucchi SE et al. Diabetes Care 212. doi: /dc A1C at Goal? No Add GLP 1 Receptor Agonist Insulin (basal) SOLVE: Baseline A1C Distribution at Insulin Initiation Patients (%) % A1C (%) The Insulin Paradox Many patients have high blood glucose levels, which puts them at risk for complications AND Insulin is the most powerful medication for lowering blood glucose BUT Many patients with poor glycemic control do not receive insulin treatment Khunti K et al, for the SOLVE Study Group. Diabetes. 211;6 (Suppl 1):A
5 Changes in A1C and Glycemic Burden (in months) A1C (%) Pre-Tx A1C Best Rx A1C Last Rx A1C Diet & Exercise N = 2319 SU N = 3394 MET N = 513 SU + MET N = 982 Insulin 9.5% PATIENTS WHO ARE NOT MANAGING THEIR DIABETES WELL.. ARE SIGNIFICANTLY MORE LIKELY TO PERCEIVE INSULIN THERAPY AS POTENTIALLY BENEFICIAL A1C > 8% (mo) A1C > 7% (mo) Brown JB et al. Diabetes Care. 24;27: Peyrot M et al. Diabetes Care. 25;28: Case: Douglas 52-Year-Old African-American Man Progression of Treatment Options for Type 2 Diabetes First MD visit after relocating for a new job - T2DM x 8 years, HTN and dyslipidemia x 15 years - 6 3, 223 lbs; BMI= A1C 6 mos ago 8.7% this visit, 8.9% Current medications (past 3 years) Metformin 1 mg BID Glipizide ER 2 mg QD Saxagliptin 5mg QD Simvastatin 4 mg HS Aspirin 81 mg QD 15 Beta-cell Function (%)* UKPDS: Beta-cell loss over time Douglas l l l l l l l l l Years From Diagnosis *Dashed line shows extrapolation forward and backward, years to 6 from diagnosis based on homeostasis model assessment (HOMA) data from UKPDS. The data points for the time of diagnosis () and the subsequent 6 years are taken from the obese subset of the UKPDS population and were determined by the HOMA model. UKPDS = United Kingdom Prospective Diabetes Study; OAD = oral antidiabetic drug. Lebovitz HE. Diabetes Rev. 1999;7: Post Hedonism Following a meal patients with poorly controlled diabetes will experience a significant rise in their post glucose values resulting in fatigue, lethargy, moodiness, irritability Overcoming Patients Resistance to Starting Insulin Replacement Therapy If baseline, pre-meal glucose levels are 24 mg/dl, post- glucose (PPG) levels can easily surpass 3 mg/dl Insulin can quickly suppress PPG excursions and improve post hedonism Unger, J. Diabetes Management In Primary Care. Lippincott
6 Common Reasons Why Patients May Resist Insulin Replacement Initiation Addressing Barriers to Insulin Initiation Fear of Needles Feeling of loss of health Insulin causes ill health Belief that insulin is unnecessary Ability to deal with insulin Fear of hypoglycemia Complexity of self-injection and pain Insulin seen as the beginning of the end Mourning related to loss of good health Observations of others (death or complications will follow introduction of insulin) Lack of understanding of disease process Not necessary with stricter dieting and increased exercise Whether the person will handle the equipment Adjust dosing Dealing with different situations Insulin Ignorance Observation of others experiences with insulin Barriers to Insulin Initiation Sense of failure Worsening disease severity Loss of control Perception of insulin ineffectiveness Fear of injections Addressing the Barriers Worsening beta-cell dysfunction is inevitable Insulin replacement expected over time Do not use insulin as threat, but as solution Control hyperglycemia to prevent damage from hyperglycemia Address insulin myths (causes complications, damages the pancreas, etc) Empower patient to take control of blood glucose Monitor glucose and provide self-adjustment algorithms Give limited trial with appropriate insulin doses Monitor for symptom improvement (nocturia, energy level, etc) Insulin pen is less threatening and more user-friendly 4-mm 32-G needles are painless Have patient inject in office Peyrot M et al. Primary Care Diabetes. 21;4(Suppl 1):S11-S18. 2 Addressing Barriers to Insulin Initiation ARS Question Barriers to Insulin Initiation Fear of hypoglycemia Insulin causes weight gain Burden of care and complexity Addressing the Barriers Low incidence, especially with basal analogs Teach patient to recognize and treat (Rule of 15) Start with basal insulin, which is associated with less weight gain More physiologic insulin delivery may minimize weight gain Metformin may offset Start basal insulin once daily Use disposable insulin pens Test once daily before breakfast, and provide simple instructions for insulin adjustment What type of insulin do you usually start with in your practice? 1. Detemir insulin 2. Glargine insulin 3. NPH insulin 4. Premixed insulin 5. Regular insulin 6. Rapid acting analog Peyrot M et al. Primary Care Diabetes. 21;4(Suppl 1):S11-S Physiologic Insulin Secretion Selecting an Insulin Regimen Plasma Insulin Breakfast Lunch Dinner Bolus, Mealtime, Prandial Insulin Start by assessing patient lifestyle, willingness to start insulin, blood glucose data, appropriate targets - Give the option of a 3-month trial - Any insulin will improve glucose control May start with a basal insulin regimen, optimize dose, and intensify with coverage if needed Basal Insulin 4: 8: 12: 16: 2: 24: 4: Time from Kruszynska Y, et al. Diabetologia. 1987; Adapted 3:
7 Insulin Delivery Devices: On-going Evolution 211 Insulin Absorption Variability (Mean Insulin Absorption) Pattern A Pattern B Both patients have identical A1C levels Which patient will most likely have the better longterm outcomes? Hypoglycemia 1945 Hyperglycemia Adapted from: Physiologic insulin replacement therapy. In: Unger Jeff. Diabetes Management in Primary Care. Lippincott, Williams and Wilkins. Philadelphia, PA. 27. P Glucose infusion rate (GIR) profiles following 4 nonconsecutive injections of identical doses (.4U/kg, thigh) in 3 patients Clamp 1 Clamp 2 Clamp 3 Clamp 4 GIR mg/(kg min) Variability in Time-action Profiles of Basal Insulins 8. NPH-insulin 8. Insulin glargine 8. Levemir Patient 1 Patient 2 Patient Time (hours) Time (hours) Time (hours) Insulins Used in Clinical Practice Rapid-acting analogs: Aspart Glulisine Lispro Short-acting insulin: Regular (soluble) Intermediate-acting insulin: NPH Human insulin 7/3: premix Reg/NPH Long-acting insulin: Detemir Glargine Reproduced with permission. T. Heise et al. Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes Diabetes 24;53: Premixed Analogs: Time (hours) Insulin lispro mix 75/25, 5/5 Biphasic insulin aspart 7/3 Adapted from Hirsch I. N Engl J Med. 25;352: Insulin Pharmacodynamics Type of Insulin Onset Peak Duration Appearance Fast-Acting Regular ½ -1 hr 2-4 hr 6-8 hr Clear Rapid-Acting Aspart/ Glulisine/ <15 min 1-2 hr 4-6 hr Clear Lispro Intermediate-Acting NPH 1-2 hr 6-1 hr 12+ hr Cloudy Long-Acting Detemir Glargine 1 hr 1.5 hr Relatively flat, max effect in 5 hr Flat, max effect in 5 hr hr Clear 24 hr Clear Advantages of Insulin Analogs Over Human Insulin: Basal Longer-acting (up to 24 hours) - Once-daily administration - Less variability from day to day Flatter biological activity (less peak) - Lower risk of nocturnal and overall hypoglycemia Less weight gain (insulin detemir) Hirsch IB. N Engl J Med. 25;352(2): Meneghini L et al. Diabetes Obes Metab. 27;9(6): Monami M et al. Diabetes Res Clin Pract. 28;81(2):
8 Advantages of Insulin Analogs Over Human Insulin: Rapid-Acting Starting Once-Daily Basal Insulin More rapid onset of action - Convenient mealtime administration - Better PPG control More rapid return to basal levels - Potentially less hypoglycemia Greater predictability For insulin-naïve patients, start basal insulin with u/kg/day, given once a day, and adjust to achieve goal Example: Douglas weighs 223 lbs Calculate his starting dose of basal insulin: 223 pounds 2.2 = 11 kg.2 units/kg x 11 kg = 2 units basal insulin Handelsman Y et al. Endocr Pract. 211;17(Suppl 2):1-53. Hirsch IB. N Engl J Med. 25;352(2): Meneghini L et al. Diabetes Obes Metab. 27;9(6): ADA. Standards of Medical Care in Diabetes 212. ADA. Diabetes Care 212; 35(1),:S4-S1 32 Monitoring Glycemic Control Insulin Detemir vs. Insulin Glargine Effect on Weight SMBG Treatment adjustment Identify glycemic burden, patterns, and variability Fasting, post, or both Allows for targeting of therapy Education Real-time feedback on glycemic response to diet, activity, and medications Detect hypoglycemia Use for real-time medication (insulin) adjustments A1C Level (%) Glycemic Control Treatment Time (weeks) No difference in hypoglycemia Weight Change (kg) Weight Gain Det QD * Det BID * Det All *P <.1; P =.12 Glarg QD 33 Rosenstock J et al. Diabetologia. 28;51(3): Self-Monitoring of Blood Glucose (SMBG) and Glycemic Control Basal Coverage Can help. Patients and their physicians better adjust therapy and assess responses to therapy Physicians and patients implement a treat-to-target approach Patients correct hyperglycemia and better adhere to treatment Detect and manage hypoglycemia Intermediate-acting insulin: NPH Long-acting insulin: Detemir Glargine Time (hours) 35 Adapted from Hirsch I. N Engl J Med. 25;352:
9 Observational, Open-Label, Treat-to-Target Study: Insulin Detemir vs NPH Insulin Added to Oral Therapy A1C Level (%) Detemir NPH *P <.1 A1C & Weight Changes Weeks +2.6 lb* +6.2 lb 7% of patients achieved A1C < 7% Hypoglycemic Events per Patient per Year Risk of Hypoglycemia P <.1 Overall Detemir + OAD NPH + OAD P <.1 Nocturnal Initiation and Adjustment of Insulin Regimens: Basal Insulin (Analog or NPH) Start once-a-day long-acting insulin analog or NPH bedtime or morning Starting dose: 1 units or.2 units/kg Titrate against FPG until in target range (7-13 mg/dl) Increase dose typically by 2 units every 3 days Can increase dose by 4 units every 3 days if BG > 18 mg/dl If hypoglycemia occurs or if BG < 7 mg/dl: Reduce dose by 4 units, or by 1% if dose > 6 units Yes A1C at goal after 2-3 months? No Hermansen K et al. Diabetologia. 24;47(Suppl 1):A273. Hermansen K et al. Diabetes Care. 26;29(6): Continue regimen, recheck A1C level every 3 months Premixed Intensify Basal-Bolus Adapted from Inzucchi SE et al. Diabetes Care April 19, 212. doi: /dc ARS Question Team Approach to Insulin Initiation Who usually is involved in insulin initiation in your practice? Physician Check all that apply (press <<send>> after each selection) 1. Physician 2. RN/PA/NP Pharmacist Patient Nurse/ Nurse Practitioner/ Physician Assistant 3. Certified diabetes educator (CDE) 4. Dietician 5. Pharmacist Dietitian Certified Diabetes Educator 39 ARS Question From your experience, patients who are provided guidance, eg, self-titration algorithms, can safely and effectively selftitrate insulin therapy. 1. Agree 2. Highly variable, depending on the patient 3. Disagree A1C Level (%) Insulin Glargine: Patient Self-Titration vs Physician Adjusted Frequent contacts with patients (12 in 24 weeks) Mixed-specialty and general medicine clinics Patients to adjust dose by 2 units Q3 days vs weekly adjustments by physicians A1C Level Baseline 24 Weeks Hypoglycemia Patient-Adjusted Physician-Adjusted Patient- Physician- Severe Symptomatic Nocturnal Adjusted Adjusted Increase graph size Davies M et al. Diabetes Care. 25;28(6): Incidence of Hypoglycemia (%)
10 Keys To Insulin Initiation In Primary Care Allow patients to self-titrate Customize insulin care plan for each patient and provide written instructions on protocol Use insulin pens for accurate insulin adjustment and delivery Teach patients how to utilize and interpret results of selfblood glucose monitoring values. Consider structured glucose testing rather than random glucose testing for all patients Prepare patients to recognize and treat hypoglycemia Insulin Intensification Unger J. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 211: Zisman A, et al. ADA Scientific Sessions. San Diego, CA P 4T: Insulin Initiation in Insulin-Naïve Patients With T2DM 78 patients: Type 2 diabetes A1C 7%-1% Maximum OAD dose Insulin naïve BMI 4 kg/m 2 Prandial insulin = aspart Basal insulin = detemir Premixed insulin = aspart 7/3 Prandial insulin TID Basal insulin OD Premix insulin BID Adapted from Holman RR et al. N Engl J Med. 29;361: Prandial TID + Basal OD Basal OD + TID Premix BID + mid-day Years Sulfonylurea therapy replaced by second insulin in the first year if: A1C 1%, or A1C 8% on 2 consecutive occasions, or A1C > 6.5% at end of year T: Results Most patients required and received intensification by 3 years Basal and insulin starts had more subjects at A1C 7.% at 3 years 1-year results: basal + OAD regimen was associated with less A1C reduction, but also with less hypoglycemia and weight gain - Sufficient intensification of basal dose 3-year results: intensification to basal + coverage achieved similar glycemic control, but maintained the weight and hypoglycemia advantages Holman RR et al. N Engl J Med. 29;361: The Study: Achievement of A1C Targets With Premixed Insulin Analog Therapy Premixed Insulin: Self-titration Algorithm Subjects (Cumulative %) ITT population* (n = 1) Mean baseline A1C level: 8.6% % (AACE) <7.% (ADA) 77 QD BID TID Pre-breakfast and Pre-dinner SMPG Adjustment <8 mg/dl 3 U 8 11 mg/dl No adjustment mg/dl + 3 U mg/dl + 6 U >18 mg/dl + 9 U Glycemic target: pre-breakfast and pre-supper self-monitored plasma glucose (SMBG) value of 8 to 11 mg/dl. *All patients enrolled in the trial. Garber AJ et al. Diabetes Obes Metab. 26;8(1): Oyer DS, INITIATEplus Study Group. Am J Med. 29;122(11):
11 Douglas Six Months Later Fasting vs Post Glucose: Relationship to A1C Level Glargine insulin 55 Units HS Wgt = 1 kg A1C: 7.8% FBG: mg/dl Oral regimen unchanged What is your next strategy? 1. Continue to increase basal dosage 2. Add a dose of premixed insulin 3. Add a dose of insulin prior to largest meal 4. Switch to basal-bolus regimen % Contribution % 7% 5% 5% 55% 45% < >1.2 A1C Range (%) Fasting plasma glucose (FPG) Post plasma glucose (PPG) 6% 4% 7% 3% 49 Monnier L et al. Diabetes Care. 23;26(3): Options When Patient Is Not at Goal With One Injection of Basal Insulin Prandial Coverage Add rapid-acting analog before meals 1% of the basal dose OR Switch to a premixed insulin analog Divide dose in half and give twice daily (before breakfast and dinner) OR Switch to basal-bolus regimen Rapid-acting analogs: Aspart Glulisine Lispro Short acting insulin: Regular (soluble) Time (hours) 51 Adapted from Hirsch I. N Engl J Med. 25;352: OPAL: Sequential Addition of Bolus Insulin at Mealtime: Change in A1C When and how do we get our patients to a basal-bolus regimen? Mean Change in A1C From Baseline to Endpoint Breakfast Group Main-Meal Group -.4 P = Lankisch MR et al. Diabetes Obes Metab. 28;1(12):
12 OPAL: Initial and Study-End Insulin Doses STEPwise: Two Intensification Strategies Insulin Amount (units) Breakfast Start Bolus Basal Breakfast End Main-Meal Start Main-Meal End Basal insulin optimization ExtraSTEP Add 1 st Add 1 st SimpleSTEP Add 2 nd Add 2 nd Add 3 rd Add 3 rd Period 1 Period 2 Period Week Prandial insulin = aspart Basal insulin = detemir s ExtraSTEP: Largest measured PPG increment; target PPG mg/dl SimpleSTEP: Largest perceived meal; target pre mg/dl Lankisch MR et al. Diabetes Obes Metab. 28;1(12): Meneghini L et al. Endocr Pract :1-26 STEPwise: Addition of First Bolus Injection STEPwise Study Conclusions Percentage of Patients (%) Breakfast Lunch Dinner Meneghini et al. Endocr Pract. 211 May 6:1-26 [Epub ahead of print]. ExtraSTEP SimpleSTEP ExtraSTEP group added insulin based on PPG measurement SimpleSTEP group added insulin based on patient assessment 58 Overall reduction in A1C of 1.2% was achieved with the addition of insulin Greatest A1C reductions were achieved with the first and second bolus injections Improvement in glycemic control was comparable in both groups Number of hypoglycemic episodes increased with increasing number of injections Basal-bolus treatment can be introduced in a more patient-friendly approach, using simple stepwise addition of insulin Meneghini, et al. Endocr Pract. 211;6: Question Do you use carbohydrate counting as a method of mealtime insulin adjustment? 1. Yes, it s my standard method for patients to self-titrate 2. Yes, but only with some patients 3. No, never use it Fixed vs Flexible Prandial Insulin Dosing T2DM (n=273) on 2 (36%) or more (64%) insulin injections daily - Baseline: A1C (8.1%-8.3%), BMI (36-37), mean DM duration (13 yr) Randomized to simple algorithm vs. carbohydrate counting Glulysine Adjustments Mean of Last 3-Day Fasting SMBG (mg/dl) Adjustments >18 Increase 8 units Increase 6 units Increase 4 units Increase 2 units 7-94 No change Decrease by the same number of units that insulin glulisine <7 was increased for that titration week, or decrease to 1% of the total insulin glargine dose 6 Bergenstal R et al. Diabetes Care. 28;31:
13 Simple Algorithm vs Carbohydrate Counting For Mealtime Insulin Adjustment A1C % BG (mg/dl) Baseline Week 25 BASELINE WEEK 24 Simple Algorithm Group Carb-Count Group Insulin dose: vs. 1.7 U/kg/d for simple vs. carb counting (P <.2) Weight gain: vs. 2.4 kg for simple vs. carb counting (P =.6) Question The result of the pre dinner finger-stick (FS) value determines the adjustment to make in: 1. Basal insulin 2. Breakfast insulin 3. Lunch insulin 4. Dinner insulin Bed Bergenstal R et al. Diabetes Care. 28;31: Suggested Basal-Bolus Adjustments: ± 2-Unit Changes Done Weekly Fix vs Flex Regimens Plasma Insulin (µu/ml) Prandial + correction Prandial + correction Prandial + correction Basal Bolus Basal daily Education Blood glucose measurement Insulin dose adjustment Fix Basic education.5 to 2 glucose profiles per week Only with the investigator during the visits Flex Basic education + carbohydrates + meal-dependent insulin dosing Daily glucose profile Self-adjustment every day FS FS FS FS 4: 8: 12: 16: 2: 24: 4: 8: Adjust basal insulin Adjust AM Adjust lunch Adjust dinner Carbohydrate-dependent dosing Insulin for blood glucose correction purposes Milek K et al. Diabetologia. 27;5(Suppl 1):S412. No No Yes, at every meal Yes, at every meal Paired Glucose Testing Can Provide Valuable Information to Patient Post-meal Delta Value >5 mg/dl >1 mg/dl Interpretation Not enough insulin used to cover carbs Insulin lag time not utilized Illness (flu) Snacking between the meal and 2-hour check time Forgot to give insulin (especially if delta >2 mg/dl) Insulin has expired or is denatured Insulin antibodies forming Insulin-to-carb mismatch Fasting Post- Pre- Post- Pre- Post- Brkfst Lunch Lunch Dinner Dinner -Investigational- Ultra Long-Acting Insulin <5 mg/dl Too much insulin (watch for hypoglycemia) Alcohol use (decreases gluconeogenesis) Insulin stacking: consider this option when the delta is NEGATIVE at 2 hours! 11
14 Ultra Long-Acting Insulin: Protracted Action Based on Formation of Multi-Hexamers Duration of Action Monomer Hexamer Molecular size Multi-hexamers Kurtzhals P, Heise T, Strauss HM, et al. American Diabetes Association 71 st Annual Scientific Sessions Abstract 42-LB. 68 Degludec Plus Metformin in T2DM versus Glargine HbA 1c (%) N= Zinman B, et al. Lancet. 211 Mar 12;377(9769): Weeks since randomization Degludec OD Degludec 3TW Glargine OD 7.4 (.1)% 7.3 (.1)% 7.2 (.1)% 69 Degludec Plus Metformin in T2DM vs. Insulin Glargine Patients With Confirmed Hypoglycemia* 25% 23% 23% Summary: Selecting Insulin Therapies Starting Strategy Basal Insulin + Oral Agent(s) Basal-Bolus Insulin Sensitizer(s) Starting Strategy Premixed Insulin Sensitizer(s) 2% 15% 1% 5% 8% % Degludec once daily Degludec three times Glargine once daily N= 236 weekly *Plasma glucose <56 mg/dl or Zinman B, et requiring assistance al. Lancet. 211 Mar 12;377(9769): Earlier stages of T2DM Elevated FPG Stable daytime BG Single daily injection Detemir Glargine NPH if cost an issue Gold standard but more complicated More flexible Long-acting: Detemir Glargine + Rapid-acting: Aspart Lispro Glulisine Elevated PPG 1-3 times per day Premixed : Human premix 7/3 Analogs Insulin lispro mix 75/25, 5/5 Biphasic insulin aspart 7/3 Self-mix: Rapid-acting analog or regular + NPH 71 Take Home Points Insulin therapy usually is needed if A1C level is > 8.% and blood glucose levels are not controlled on multiple OADs In most situations, first address the fasting blood sugars with basal insulin therapy - Monitor blood glucose and optimize insulin doses - Continue OADs or adjust dosages if necessary Start bolus insulin at the largest meal or the one with the highest post blood glucose levels (usually breakfast) Fixed insulin doses are effective and safe for basal/bolus therapy in type 2 diabetes Encourage and empower your patients! 72 Post-test Question #1 In patients on oral T2DM agents, at what A1C level should insulin therapy be initiated? 1. >7.5% 2. >8.% 3. >8.5% 4. >9.% 5. Any of the above 73 12
15 Post-Test Question #2 You seek to initiate insulin therapy in a poorly-controlled patient but she thinks this will be too complex for her to do. How will you address this? Check all that apply (press <<send>> after each selection) 1. Tell her that insulin is her only option at this point in time 2. Institute self-adjustment algorithms with glucose monitoring 3. Start with basal insulin twice daily 4. Address insulin myths that it causes complications, damages the pancreas 5. Institute a pre-mixed fixed-dose insulin regimen Post-Test Question #3: A pre-/post- blood glucose delta value that s less than 5 mg/ml might indicate: 1. Concurrent illness, eg, flu 2. Missed previous insulin dose 3. Previous insulin dose is too high 4. Insulin solution has expired or is denatured Questions 13
Session 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives
Session 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives 1. Design strategies to help patients overcome cultural barriers to using insulin,
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationIntensifying Insulin Therapy
Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning
More informationTherapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2
Ministry of Health, Malaysia 2010 First published March 2011 Perkhidmatan Diabetes dan Endokrinologi Kementerian Kesihatan Malaysia Practical guide to Insulin Therapy in Type 2 Diabetes Mellitus Quick
More informationAlgorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
PL Detail-Document #300128 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2014 Initiation and Adjustment of Insulin Regimens for Type
More informationIntensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
More informationInsulin Therapy. Endocrinologist. H. Delshad M.D. Research Institute For Endocrine Sciences
Insulin Therapy H. Delshad M.D Endocrinologist Research Institute For Endocrine Sciences Primary Objectives of Effective Management A1C % 9 8 Diagnosis SBP mm Hg LDL mg/dl 7 145 130 140 100 Reduction of
More informationInsulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types
Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by
More informationInsulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net
Insulin: Breaking Barriers Enhancing Therapies Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net Questions To Address Who are candidates for insulin? When do we start insulin? How do the different types of
More informationPresent and Future of Insulin Therapy: Research Rationale for New Insulins
Present and Future of Insulin Therapy: Research Rationale for New Insulins Current insulin analogues represent an important advance over human insulins, but clinically important limitations of these agents
More informationWorkshop A Tara Kadis
Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system
More informationDiabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
More informationInsulin Initiation and Intensification
Insulin Initiation and Intensification ANDREW S. RHINEHART, MD, FACP, CDE MEDICAL DIRECTOR AND DIABETOLOGIST JOHNSTON MEMORIAL DIABETES CARE CENTER Objectives Understand the pharmacodynamics and pharmacokinetics
More informationA Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or
A Simplified Approach to Initiating Insulin When to Start Insulin: 1. Fasting plasma glucose (FPG) levels >250 mg/dl or 2. Glycated hemoglobin (A1C) >10% or 3. Random plasma glucose consistently >300 mg/dl
More informationDiabetes: When To Treat With Insulin and Treatment Goals
Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy
More informationInsulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults
Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults Stock # 45-11647 Revised 10/28/10 Glycemic Goals 1,2 Individualize goal based on patient risk factors A1c 6%
More informationPresented By: Dr. Nadira Husein
Presented By: Dr. Nadira Husein I have no conflict of interest Disclosures I have received honoraria/educational grants from the following: Novo Nordisk, Eli Lilly, sanofi-aventis, Novartis, Astra Zeneca,
More informationThe first injection of insulin was given on
EFFECTIVE USE OF INSULIN THERAPY IN TYPE 2 DIABETES * Bernard Zinman, MDCM ABSTRACT Type 2 diabetes is a progressive disease; an individual s ability to secrete insulin in increasing amounts to overcome
More informationINPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
More informationADJUSTING INSULIN DOSES CONFLICTS OF INTEREST
ADJUSTING INSULIN DOSES CONFLICTS OF INTEREST Vahid Mahabadi, MD Research grants from Sanofi and Amylin Pharmaceutical Companies Mayer B. Davidson, MD Advisory Board Sanofi Pharmaceutical Company Chief
More informationInsulin therapy in type 2 diabetes When and how? Disclosures. Learning Objectives. None relevant to today s talk
Insulin therapy in type 2 diabetes When and how? Cecilia C Low Wang, MD Univ Colorado AMC SOM Department of Medicine Division of Endocrinology, Metabolism, and Diabetes Disclosures None relevant to today
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More informationINSULIN INTENSIFICATION: Taking Care to the Next Level
INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely
More informationINSULIN ALGORITHM FOR TYPE 2 DIABETES MELLITUS IN CHILDREN 1 AND ADULTS
Publication # 45-11647 Targets*
More informationType 2 Diabetes Adult Outpatient Insulin Guidelines Sutter Medical Foundation. February 2011.
Type 2 Diabetes Adult Outpatient Insulin Guidelines. GENERAL RECOMMENDATIONS Start insulin if A1C and glucose levels are above goal despite optimal use of other diabetes medications. (Consider insulin
More informationStarting patients on the V-Go Disposable Insulin Delivery Device
Starting patients on the V-Go Disposable Insulin Delivery Device A simple guide for your practice For adult patients with Type 2 diabetes on basal insulin who need to take the next step Identify appropriate
More informationIntensifying Insulin In Type 2 Diabetes
Intensifying Insulin In Type 2 Diabetes Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine University of North Dakota School of Medicine and Health Sciences Assistant
More informationHow To Initiate Insulin
Initiation and Titration of Insulin Analogs in the Patient with Type 2 Diabetes Supported by an educational grant from Novo Nordisk Inc. This program is supported by an educational grant from Novo Nordisk
More informationAgainst All Odds: Improving Insulin Use in T2DM Through Individualized Clinical Decision Making
SESSION 3 10:30am 12pm Against All Odds: Improving Insulin Use in T2DM Through Individualized Clinical Decision Making SPEAKERS Frank Lavernia, MD George Dailey III, MD Carol Wysham, MD Presenter Disclosure
More informationStarting Insulin. Disclosures. Starting Insulin. Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres
Starting Insulin Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres Disclosures Scientific Consultant Abbott, AstraZeneca, GSK, Merck, Sanofi-Aventis, Janssen- Ortho, Servier
More informationWhen and how to start insulin: strategies for success in type 2 diabetes
1 When and how to start insulin: strategies for success in type diabetes Treatment of type diabetes in 199: with each step treatment gets more complex Bruce H.R. Wolffenbuttel, MD PhD Professor of Endocrinology
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationTreatment Approaches to Diabetes
Treatment Approaches to Diabetes Dr. Sarah Swofford, MD, MSPH & Marilee Bomar, GCNS, CDE Quick Overview Lifestyle Oral meds Injectables not insulin Insulin Summary 1 Lifestyle & DM Getting to the point
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationMany patients with type 2 diabetes will ultimately need
SUPPLEMENT TO JAPI april 2011 VOL. 59 17 Insulin Initiation and Intensification: Insights from New Studies Ajay Kumar 1, Sanjay Kalra 2 Abstract Tight glycemic control is central to reducing the risk of
More informationDiabetes and the Elimination of Sliding Scale Insulin. Date: April 30 th 2013. Presenter: Derek Sanders, D.Ph.
Diabetes and the Elimination of Sliding Scale Insulin Date: April 30 th 2013 Presenter: Derek Sanders, D.Ph. Background Information Epidemiology and Risk Factors Diabetes Its Definition and Its Impact
More informationPrinciples on Insulin Treatments. Insulin & Type 2 Diabetes. Natural History of Type 2 Diabetes. Why Consider Insulin Early?
Principles on Treatments & Type 2 Diabetes Jessica Castle, MD Assistant Professor, OHSU Harold Schnitzer Diabetes Health Center Natural History of Type 2 Diabetes Severity of Diabetes UKPDS: Over Time,
More informationInsulin Therapy for Optimizing Glycemic Control in Type 2 DM. Puntip Tantiwong Department of Medicine Maharat Nakhon Ratchasima Hospital 22 May 2013
Insulin Therapy for Optimizing Glycemic Control in Type 2 DM Puntip Tantiwong Department of Medicine Maharat Nakhon Ratchasima Hospital 22 May 2013 Case 1 A 45 years-old Thai female with T2DM for 3 years
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationEmerging Challenges in Primary Care: 2016. Insulin Management of Type 2 Diabetes: Designing Treatments and Overcoming Barriers
Emerging Challenges in Primary Care: 2016 Insulin Management of Type 2 Diabetes: Designing Treatments and Overcoming Barriers Faculty Richard S. Beaser, MD Senior Staff Physician Chair, Continuing Medical
More informationDiabetes Treatment in a New Era: When to Begin Insulin and How to deliver it.
Diabetes Treatment in a New Era: When to Begin Insulin and How to deliver it. Objectives 1. Briefly review the evolution of insulin therapy. 2. Identify the types of insulin currently available for treatment
More informationPrimary Care Type 2 Diabetes Update
Primary Care Type 2 Diabetes Update May 16, 2014 Presented by: Barb Risnes APRN, BC-ADM, CDE Objectives: Discuss strategies to address common type 2 diabetes patient management challenges Review new pharmacological
More informationCLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies
Insulins CLASS OBJECTIVES Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies INVENTION OF INSULIN 1921 The first stills used to make insulin
More informationDr. John Bucheit, Pharm.D., BCACP, CDE Clinical Assistant Professor Mercer University College of Pharmacy
Dr. John Bucheit, Pharm.D., BCACP, CDE Clinical Assistant Professor Mercer University College of Pharmacy Disclosures to Participants Requirements for Successful Completion: For successful completion,
More informationTYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES
TYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES Non-insulin regimes Basal insulin only (usually with oral agents) Number of injections 1 Regimen complexity Low Basal insulin +1 meal-time rapidacting insulin
More informationMost patients with T2DM will eventually require insulin therapy. ADA Glycemic Control Targets. What are some of the obstacles?
ADA Glycemic Control Targets A1C < 7% Preprandial plasma glucose 70-130 mg/dl Postprandial plasma glucose (PPG)
More informationThe prevalence of type 2 diabetes
Insulin Therapy for Management of Type 2 Diabetes Mellitus: Strategies for Initiation and Long-term Patient Adherence Steven H. Barag, DO Effective glycemic control is essential to minimize the long-term
More informationIMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL
464 IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL PRACTICE STEPHAN A SCHREIBER AND ANIKA RUßMAN ABSTRACT
More informationStarting or Changing Insulin Therapy For the Generalist Physician
Starting or Changing Insulin Therapy For the Generalist Physician SGIM National Meeting 2008 DC Dugdale, MD, FACP Division of GIM, University of Washington Dawn E. DeWitt MD, FACP, FRACP University of
More informationLipodystrophy: Metabolic and Clinical Aspects. Resource Room Slide Series
Lipodystrophy: Metabolic and Clinical Aspects Resource Room Slide Series Current Thinking About the Diagnosis and Treatment of the Insulin-Resistant State: How to Use Insulin Therapy Irl B. Hirsch, MD
More informationMy Doctor Says I Need to Take Diabetes Pills and Insulin... What Do I Do Now? BD Getting Started. Combination Therapy
My Doctor Says I Need to Take Diabetes Pills and Insulin... What Do I Do Now? BD Getting Started Combination Therapy How Can Combination Therapy Help My Type 2 Diabetes? When you have type 2 diabetes,
More informationTreatment of Type 2 Diabetes
Improving Patient Care through Evidence Treatment of Type 2 Diabetes This information is based on a comprehensive review of the evidence for best practices in the treatment of type 2 diabetes and is sponsored
More informationType 2 Diabetes - Pros and Cons of Insulin Administration
Do we need alternative routes of insulin administration (inhaled insulin) in Type 2 diabetes? Cons: Suad Efendic Karolinska Institutet, Sweden The Diabetes Management Situation Today Diabetes is a growing
More informationInitiating & titrating insulin & switching in General Practice Workshop 1
Initiating & titrating insulin & switching in General Practice Workshop 1 Workshop goal To make participants comfortable in the timely initiation and titration of insulin Progression of Type 2 Diabetes
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
Page 1 of 5 PURPOSE To assure that DOP inmates with Diabetes, who require insulin therapy, are receiving high quality Primary Care for their condition. POLICY All DOP Primary Care Providers are to follow
More informationInsulin switch & Algorithms Rotorua GP CME June 2011. Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB
Insulin switch & Algorithms Rotorua GP CME June 2011 Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB Goal of workshop Insulin switching make the necessary move Ensure participants are confident with Recognising
More informationDiabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
More informationGlycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol
Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Ruth LaCasse Kalish, RPh Department of Pharmacy Objectives Review the current practice at UConn Health with sliding
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationInsulin. Regimens Characteristics / categorization Pharmacokinetics / pharmacodynamics Adverse effects Compatibility Costs
Insulin Regimens Characteristics / categorization Pharmacokinetics / pharmacodynamics Adverse effects Compatibility Costs Insulins Rapid-acting Inhaled Short-acting Basal/ Intermediate Basal Pre-mixed
More informationINSULINThere are. T y p e 1 T y p e 2. many different insulins for
T y p e 1 T y p e 2 INSULINThere are many different insulins for Characteristics The three characteristics of insulin are: Onset. The length of time before insulin reaches the bloodstream and begins lowering
More informationsecond of a two-article series. The first, Clinical Considerations for Insulin
Navid Saadat, MD Clinical Considerations for Insulin Pharmacotherapy in Ambulatory Care, Part Two: Review of Primary Literature and an Evidence-Based Approach for Treatment Maria Miller Thurston, 1 John
More informationA 1c Control in a Primary Care Setting: Self-titrating an Insulin Analog Pre-mix (INITIATEplus Trial)
CLINICAL RESEARCH STUDY A 1c Control in a Primary Care Setting: Self-titrating an Insulin Analog Pre-mix (INITIATEplus Trial) David S. Oyer, MD, a Mark D. Shepherd, MD, b Franklin C. Coulter, MD, c Anuj
More informationOptimizing Insulin Therapy for Patients with Type 2 Diabetes: Existing Challenges and New Opportunities to Improve Care
1 2:15 pm Optimizing Insulin Therapy for Patients with Type 2 Diabetes: Existing Challenges and New Opportunities for Improved Care SPEAKERS Yehuda Handelsman, MD, FACP, FACE, FNLA Javier Morales, MD Presenter
More informationA new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration
of nurse A new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration 1. Check times for point of care meter blood glucose testing. Pre-Breakfast
More informationVolume 01, No. 08 November 2013
State of New Jersey Department of Human Services Division of Medical Assistance & Health Services New Jersey Drug Utilization Review Board Volume 01, No. 08 November 2013 TO: SUBJECT: PURPOSE: Physicians,
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More informationCalculating Insulin Dose
Calculating Insulin Dose First, some basic things to know about insulin: Approximately 40-50% of the total daily insulin dose is to replace insulin overnight, when you are fasting and between meals. This
More informationBASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS
BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS C O N T A C T D I A B E T E S S E R V I C E S F O R M O R E I N F O R M A T I O N 8 4 7-9 1 7-6 9 0 7 THIS SLIDE PRESENTATION WAS PREPARED BY SUE DROGOS,
More informationEveryday Practice: Diabetes Mellitus
THE NATIONAL MEDICAL JOURNAL OF INDIA VOL. 20, NO. 5, 2007 245 Everyday Practice: Diabetes Mellitus Insulin therapy for patients with type 2 diabetes mellitus NISHA R. S., E. BHATIA INTRODUCTION India
More informationInsulin initiation in type 2
Earn 3 CPD Points online Insulin initiation in type 2 diabetes This text is derived from the insulin initiation video presentation by Dr Ted Wu and includes all relevant references Dr Ted Wu Staff Specialist,
More informationInsulin initiation in type 2 diabetes: Experience and insights
Insulin initiation in type 2 diabetes: Experience and insights Joan Everett A diagnosis of type 2 diabetes can be devastating for the individual and their family. Furthermore, many people with diabetes
More informationGlobal Guideline for Type 2 Diabetes
INTERNATIONAL DIABETES FEDERATION, 2005 Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes Chapter 10: Glucose control: insulin therapy Copyright All rights reserved. No part of this publication
More informationTen Ways to Prevent Insulin-Use Errors in Your Hospital. ASHP Research and Education Foundation May 14, 2014
Ten Ways to Prevent Insulin-Use Errors in Your Hospital ASHP Research and Education Foundation May 14, 2014 To Ask Questions and Adjust the Control Panel Expand or Collapse Type your question here Faculty
More information(30251) Insulin SQ Prandial Carbohydrate
Diagnosis Patient MUST BE educated using carbohydrate counting for prial insulin coverage before hospitalization to be eligible for this order set Nursing Metered Glucose (Single Select Section) Metered
More informationStrengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours
Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours Presented by New York State Council of Health system Pharmacists October 18 19, 2013 St. John s University,
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationDisclosures. Types of Diabetes Mellitus. Type 1 Diabetes Mellitus. Principles of Basal-Bolus Insulin Therapy and Carbohydrate Counting
Principles of Basal-Bolus Insulin Therapy and Carbohydrate Counting Disclosures I do not have any relevant financial relationships with any commercial interests. Henry K. Driscoll, MD, FACP Huntington
More informationConsensus Evidence-based Guidelines for Insulin Initiation, Optimization and Continuation in Type 2 Diabetes Mellitus
supplement to Journal of the association of physicians of india Published on 1st of every month 1st July, 2014 VOL. 62 49 Consensus Evidence-based Guidelines for Insulin Initiation, Optimization and Continuation
More informationMANAGEMENT OF TYPE - 1 DIABETES MELLITUS
MANAGEMENT OF TYPE - 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria
More informationYour Insulin Adjustment Workbook Yes, You Can Do It!
S T AY I N G O N T A R G E T TARGET THERAPY Staying on Target TM Your Insulin Adjustment Workbook Yes, You Can Do It! YES, YOU CAN DO IT! Your How-To Guide for Adjusting Basal and Bolus Insulin This workbook
More informationDisclosure. Learning Objectives. Glycemic Control & Vascular Complications in T2DM. Baseline Characteristics of the Landmark Trials in T2DM
Disclosure Insulin Therapy in Patients with Type 2 Diabetes: Current and Emerging Basal Insulins Investigational agents will be discussed during this presentation Andrew Ahmann, MD, MS Professor of Medicine
More informationAdd: 2 nd generation sulfonylurea or glinide or Add DPP-4 inhibitor Start or intensify insulin therapy if HbA1c goals not achieved with the above
Guidelines for Type Diabetes - Diagnosis Fasting Plasma Glucose (confirm results if borderline) HbAIC Normal FPG < 00 < 5.5 Impaired Fasting Glucose (IFG) 00 to < 5.7%-.5% Diabetes Mellitus (or random
More informationSUBJECT: DIABETES MEDICATION MANAGEMENT PROTOCOLS
SUBJECT: DIABETES MEDICATION MANAGEMENT PROTOCOLS PURPOSE To establish a process that will enable Certified Diabetes Educators (CDE) and/or staff with Board Certification in Advanced Diabetes Management
More informationSafety and Effectiveness of Modern Insulin Therapy: The Value of Insulin Analogs
STEPHEN BRUNTON, MD Cabarrus Family Medicine Residency Program, Charlotte, NC Safety and Effectiveness of Modern Insulin Therapy: Dr Brunton is director of faculty development at the Cabarrus Family Medicine
More informationFundamentals of Diabetes Care Module 5, Lesson 1
Module 5, Lesson 1 Fundamentals of Diabetes Care Module 5: Taking Medications Healthy Eating Being Active Monitoring Taking Medication Problem Solving Healthy Coping Reducing Risks Foundations For Control
More informationAACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM
AACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2013 TASK FORCE Alan J. Garber, MD, PhD, FACE, Chair Martin J. Abrahamson, MD Joshua I. Barzilay, MD, FACE Lawrence Blonde, MD, FACP, FACE Zachary T. Bloomgarden,
More informationTYPE2DIABETES INSULIN TREATMENT 2009 UPDATE ON A HEALTHCARE PROFESSIONAL S GUIDE TO TREATMENT BY J. ROBIN CONWAY, MD. www.diabetesclinic.
TYPE2DIABETES INSULIN TREATMENT 2009 UPDATE ON A HEALTHCARE PROFESSIONAL S GUIDE TO TREATMENT BY J. ROBIN CONWAY, MD www.diabetesclinic.ca Author: Dr. Robin Conway Note to readers The contents herein represent
More informationPump Therapy Indications:
Insulin Pumping Getting Started March 7, 2008 Clinical Pearls To understand the rational behind pump therapy To explore patient preferences for and against insulin pump therapy Realistic expectations for
More informationThere seem to be inconsistencies regarding diabetic management in
Society of Ambulatory Anesthesia (SAMBA) Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Review of the consensus statement and additional
More informationManagement of Diabetes: A Primary Care Perspective. Presentation Outline
Management of Diabetes: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Presentation Outline
More informationInsulin use in Type 2 Diabetes
Insulin use in Type 2 Diabetes Kenneth Izuora, MD, MBA University of Nevada School of Medicine May 16, 2015 Conflict of Interest I have received research support from Sanofi in the past. 2 Learning Objectives
More informationInsulin/Diabetes Calculations
Insulin/Diabetes Calculations Dr. Aipoalani St Lukes Endocrinology Goals Describe various calculations for insulin dosing Understand importance of the total daily dose (TDD) of insulin Be able to calculate
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationOptimizing Insulin Therapy for Patients with Type 2 Diabetes: Existing Challenges and New Opportunities to Improve Care
1 2:15pm Optimizing Insulin Therapy for Patients with Type 2 Diabetes: Existing Challenges and New Opportunities for Improved Care SPEAKERS Lawrence Blonde, MD, FACP, FACE Bruce W. Bode, MD, FACE Presenter
More informationScottish Medicines Consortium
Scottish Medicines Consortium insulin glulisine for subcutaneous injection 100 units/ml (Apidra ) No. (298/06) Sanofi Aventis 4 August 2006 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationINSULIN FOR GESTATIONAL and PREGESTATIONAL DIABETES
INSULIN FOR GESTATIONAL and PREGESTATIONAL DIABETES There have been several changes in the management of diabetes during pregnancy, including the use of insulin analogs. The Sweet Success Guidelines, revised
More information